





































































































Purpura in a 9-Month Old: Diagnosing and
Managing an Ultra-rare Disorder
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Summary: Hereditary thrombotic thrombocytopenic purpura is an
ultra-rare disorder caused by biallelic mutations in the ADAMTS13
gene. Because it can be difficult to diagnose, plasma ADAMTS13
activity assessment should be considered in patients with throm-
bocytopenia, anemia, and schistocytes on peripheral blood smear.
We present the diagnostic evaluation of a patient with hereditary
thrombotic thrombocytopenic purpura. Genetic testing revealed
one known pathogenic mutation and one novel mutation of
ADAMTS13 classified as likely pathogenic on the basis of parental
genetic testing and in silico analyses. We further discuss off-label use
of prophylactic plasma-derived Factor VIII (Koate-DVI) and the
benefit of rare disease registries.
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CASE REPORT
A 9-month-old girl presented to the emergency department with
fever, cough, rhinorrhea, and poor oral intake. These symptoms were
present for 2 weeks but worsened over the previous 2 days. She had a
history of thrombocytopenia in the postnatal period, with a platelet
count nadir of 41,000×109/L, which spontaneously resolved by 3
weeks of life. On examination, she had coarse breath sounds, bilateral
acute otitis media, pale and mottled skin, and delayed capillary refill.
She lacked lymphadenopathy or hepatosplenomegaly. Respiratory
syncytial virus testing was positive. Laboratory studies revealed
normal chemistries, creatinine, and transaminases. Complete blood
count (CBC) revealed normocytic anemia, with hemoglobin of
8.1 g/dL and mean corpuscular volume of 78.7 fL. Platelet count was
13,000×109/L, and leukocyte count was 11.9× 109/L. Uncorrected
reticulocyte count was 2.8%. Lactate dehydrogenase was elevated at
685U/L, and haptoglobin was undetectable. Prothrombin time,
partial thromboplastin time, and fibrinogen were normal. Out of
clinical concern for sepsis, blood cultures were drawn, she was given
ceftriaxone, and sent to a referral center.
At the referral center, CBC confirmed anemia and thrombo-
cytopenia. Peripheral blood smear demonstrated schistocytes and
no blasts (Fig. 1A). Direct antiglobulin test returned negative.
She was empirically given intravenous immune globulin at a dose of
1 g/kg for presumed autoimmune cytopenias and was transfused
with platelets and packed red blood cells. Two days later, her
hemoglobin had risen to 12.3 g/dL and platelet count to 430× 109/L.
She was followed with serial CBCs. With viral respiratory or
gastrointestinal illnesses, she developed recurrence of her throm-
bocytopenia. Repeat peripheral blood smear performed while
the patient was well demonstrated slight schistocytes (Fig. 1B).
Congenital thrombotic thrombocytopenic purpura/hereditary
thrombotic thrombocytopenic purpura (hTTP) (Upshaw-Schulman
syndrome) was suspected, and ADAMTS13 (a disintegrin and
metalloprotease with thrombospondin type 1 motif, member 13)
testing revealed activity of < 5% with no evidence of functional
inhibitor, leading to a diagnosis of hTTP.
Thrombotic thrombocytopenic purpura (TTP) is characterized
by deficient activity of the protease ADAMTS13 which cleaves high
molecular weight von Willebrand Factor multimers into smaller, less-
active fragments. In the absence of functional ADAMTS13, highly-
active high molecular weight von Willebrand Factor multimers
accumulate, leading to spontaneous microvascular thrombosis and
microangiopathic hemolytic anemia. TTP can be inherited, due to
mutations in the ADAMTS13 gene, or acquired, due to autoanti-
bodies which lead to inhibition and/or clearance of ADAMTS13.1,2
The patient’s thrombocytopenia in the neonatal period may
have represented undiagnosed TTP, although her hemoglobin and
peripheral blood smear were reported as normal at that time. After
her diagnosis was established, the patient underwent screening brain
magnetic resonance imaging examination, which revealed no
detectable abnormality, such as subclinical infarction.
Confirmatory genetic testing of the patient and her parents
revealed 2 paternally-acquired mutations in the ADAMTS13
(GRCh37, NM_139025.4) gene: c.1787C>T (p.Ala596Val) on
exon 16 and c.1392C>T (p.Gly464= ) on exon 12, with the former
known to be pathogenic3 and the latter a variant of uncertain sig-
nificance (VUS). In addition, the patient had a maternally acquired
c.548T>A (p.Leu183Gln) missense mutation on exon 6, which was
reported by the reference laboratory (Fulgent Genetics, Temple
City, CA) as a VUS.
In silico analyses were performed to obtain evidence of path-
ogenicity of the maternally acquired mutation. Mutational analysis
using subRVIS4 (subrvis.org) identified the location of the mutation
as functionally important. ADAMTS13 function is calcium-depend-
ent, and the residues surrounding this amino acid are thought to be
important for calcium binding.5 Furthermore, in silico analyses using
PolyPhen 2 HumVar6 (http://genetics.bwh.harvard.edu/pph2/) and
Mutation Assessor7 (http://mutationassessor.org/r3/) yielded classi-
fications of this mutation as probably damaging. Finally, the alter-
ation was absent from 3 large population genetics databases:
1000 Genomes (www.internationalgenome.org),8 ESP (http://evs.gs.
washington.edu/EVS/),9 and gnomAD (https://gnomad.broadinstitute.
org/).10 On the basis of this evidence, we were able to classify the
maternally acquired c.548T>A (p.Leu183Gln) mutation as likely
pathogenic per American College of Medical Genetics and Genomics
(ACMG) criteria.11 Furthermore, communication with the Hereditary
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TTP Registry (www.ttpregistry.net) revealed a registered patient
diagnosed with hTTP at 5 months of age who had a T>C
(p.Leu183Pro) change of the same nucleotide (c.548) that was
altered T>A in our patient. The registry patient similarly suffered
from thrombocytopenia, hemolysis, and anemia in the immediate
postnatal period.
DISCUSSION
hTTP is a chronic, lifelong disease with no cure. Acute
episodes of anemia and thrombocytopenia are treated with
infusions of fresh frozen plasma (FFP), which contains
ADAMTS13, to replete the deficient protein. It is common
practice to prophylactically treat patients with routine
(ie, every 2 to 3 wk) FFP to prevent acute episodes of
thrombotic microangiopathy.1 The observation that one
plasma-derived Factor VIII product (Koate-DVI; Kendrion
Biopharma) incidentally contains a relatively high concen-
tration of ADAMTS1312 has led to off-label use in patients
with hTTP.13 Furthermore, recombinant ADAMTS13 is the
subject of an ongoing phase III randomized cross-over
clinical trial (ClinicalTrials.gov NCT03393975) comparing
prophylactic versus on-demand dosing with a continuation
arm. The preceding phase I study reported ADAMTS13
pharmacokinetic parameters similar to what was observed
with FFP infusion.14
To gather more information about this rare disease, an
international Hereditary TTP Registry15 (www.ttpregistry.
net) exists to combine patient data and yield insights into the
pathogenesis and management of hTTP. The patient was
enrolled in the registry, which provided supplemental infor-
mation to the treating team to confirm the likely pathoge-
nicity of one of the patient’s genetic VUS and also connected
the treatment team with other providers who care for patients
with hTTP.16
The patient was initially treated with on-demand FFP.
However, she required infusions approximately every 4
weeks due to acute exacerbations. For prevention of acute
TTP exacerbations, her parents elected to initiate prophy-
lactic management with Koate-DVI to allow for the con-
venience of rapid, small-volume, in-home infusion and also
to potentially reduce the risk of transfusion-associated viral
diseases using a solvent/detergent treated product. She was
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FIGURE 1. Peripheral blood smears (A) on initial presentation to the referral intensive care unit and (B) while the patient was well
demonstrate schistocytes and helmet cells (arrows).




















Response of Platelet Count to Treatment Approaches
Koate-DVI (25 units/kg)
Koate-DVI (50 units/kg)




FIGURE 2. Platelet count over time. Arrows note the time of treatment administration. Acute thrombotic thrombocytopenic purpura
episodes are noted with asterisks. Shaded area denotes reference range for platelet count.
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initially started at a dose of 25 U/kg intravenously every 2
weeks; however, she experienced breakthrough acute TTP
episodes, and her dose was modified several times before
arriving at the present dose of 25 U/kg on Mondays and
40 U/kg on Thursdays. Thus far, the patient has been
treated for 4 acute episodes with Koate-DVI and demon-
strated improvement of anemia and thrombocytopenia
within 2 days of receiving “rescue” doses (Fig. 2).
In summary, hTTP is an ultra-rare condition for which
diagnosis may be delayed. ADAMTS13 assay should be
considered for patients with anemia, thrombocytopenia, and
schistocytes on peripheral blood smear. In this patient, per-
sistence of schistocytes while she was clinically well was the
clue which led to the diagnosis of hTTP. Patients may be
treated with FFP or Koate-DVI. Patients with severe disease
may require frequent dosing to prevent recurrent episodes.
An ongoing trial of recombinant ADAMTS13 may lead to
the availability of a new treatment for this disease in the near
future. Through collaboration with a genetic counselor, we
were able to establish a novel mutation as likely pathogenic,
and we experienced that disease registries can be invaluable to
clinicians when caring for patients with rare diseases.
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